Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD312 CAR-T cell
- Development stage
- Preclinical
- Lead developer
- Tianjin First Central Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CD312 CAR-T cell is an investigational chimeric antigen receptor (CAR) T-cell therapy targeting CD312 (also known as ENPP3), a cell surface marker expressed on acute myeloid leukemia (AML) blasts and leukemic stem cells (LSCs). Developed by researchers at Tianjin First Central Hospital and Nankai University, this therapy aims to treat refractory and relapsed AML by specifically targeting and eliminating malignant cells while sparing normal hematopoietic stem cells. Research presented at ASH 2024 also explores a split CAR-T configuration targeting both CD312 and TIM-3 to mitigate antigen escape and improve the eradication of LSCs.
- Other names
- ENPP3 CAR-T cellENPP-3 CAR-T cellENPP 3 CAR-T cellanti-CD312 CAR-T cellanti-CD-312 CAR-T cellanti-CD 312 CAR-T cell
02
Targets
ENPP3 (Ectonucleotide pyrophosphatase/phosphodiesterase 3)HAVCR2 (T cell immunoglobulin and mucin domain-containing protein 3)
Beyond the preview
Go deeper on CD312 CAR-T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD312 CAR-T cell.